P3.13-01 Detecting ALK Rearrangements in NSCLC Patients: IHC, FISH or NGS Fusion?

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1841
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Variable Response to ALK Inhibitors in NSCLC With a Novel MYT1L-ALK Fusion

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

ALK (D5F3) CDx: An Immunohistochemistry Assay to Identify ALK-positive NSCLC Patients

Pharmacogenomics and Personalized Medicine
Molecular MedicinePharmacology
2018English

P3.17-01 PD-L1 Expression, EGFR Mutations and ALK Expression in Non-Small Cell Lung Cancer (NSCLC) Patients From Brazil

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-99 Detecting HER2 Alterations by Next Generation Sequencing (NGS) in Patients With Advanced NSCLC From the United States and China

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

Pcn216 - Contemporary Real-World Evidences on Alk+ NSCLC Patients in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

P3.13-34 RET Gene, a New Choice for NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.13-11 Advanced NSCLC Treated With Gefitinib or Erlotinib for Five Years or Longer - Retrospective Slovakian Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Brigatinib Bei ALK-positivem NSCLC

Im Focus Onkologie
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy